Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

Although common evolutionary principles drive the growth of cancer cells regardless of the
tissue of origin, the microenvironment in which tumours arise substantially differs across …

Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Purpose: Metastatic castration-resistant prostate cancer (mCRPC) remains a disease with
high unmet medical need, as most patients do not achieve durable response with available …

Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients
progress to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) signaling …

Prostate cancer (PC) remains a leading cause of cancer-related deaths among men
worldwide, despite continuously improved treatment strategies. Patients with metastatic …

Abstract Switch/sucrose-nonfermentable (SWI/SNF) chromatin-remodeling complexes are
critical regulators of chromatin dynamics during transcription, DNA replication, and DNA …

The targeted alpha therapy radium-223 (223Ra) can prolong survival in men with castration-
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …

Background The intractability of castration-resistant prostate cancer (CRPC) is exacerbated
by tumour heterogeneity, including diverse alterations to the androgen receptor (AR) axis …